Given China’s relatively weak innovative and regulatory capacity compared to developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: i) set strategic vaccine R&D goals and achieve broad consensus; ii) strengthen coordination across government agencies; and iii) adopt the state-driven collaborative model.
What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective